Azevan
1 known investors
Azevan Pharmaceuticals develops small-molecule vasopressin V1a receptor antagonists (including SRX246, SRX251/AVN849) to treat pathological aggression and emotional dysregulation across CNS disorders such as Huntington's disease, Fragile X syndrome, intermittent explosive disorder, and mild traumatic brain injury. The company runs clinical-stage neuropsychiatric drug programs targeting underserved patient populations with no approved targeted therapies.
Investors · 1
Non-dilutive funding · 12 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $3.2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $501.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $4.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $3.3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2011 | $1.8M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2011 | $141.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $349.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2009 | $226.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2002 | $498.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2002 | $100K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2002 | — |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2000 | $100K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Azevan do?
- Azevan Pharmaceuticals develops small-molecule vasopressin V1a receptor antagonists (including SRX246, SRX251/AVN849) to treat pathological aggression and emotional dysregulation across CNS disorders such as Huntington's disease, Fragile X syndrome, intermittent explosive disorder, and mild traumatic brain injury. The company runs clinical-stage neuropsychiatric drug programs targeting underserved patient populations with no approved targeted therapies.
- Who are Azevan's investors?
- Azevan's investors include Scientific Health Development.